Lymphoma, Follicular

• 

  Subject Areas on Research

  • A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. 
  • A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. 
  • A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin lymphomas: a Hoosier Oncology Group Study. 
  • A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance). 
  • A role for secondary V(D)J recombination in oncogenic chromosomal translocations? 
  • Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. 
  • Associations between anthropometry, cigarette smoking, alcohol consumption, and non-Hodgkin lymphoma in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. 
  • B-cell lymphoma with hyaline vascular Castleman disease-like features: a clinicopathologic study. 
  • Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy. 
  • CD5-positive follicular lymphoma: clinicopathologic correlations and outcome in 88 cases. 
  • CREBBP and STAT6 co-mutation and 16p13 and 1p36 loss define the t(14;18)-negative diffuse variant of follicular lymphoma. 
  • Childhood malignant non-Hodgkin lymphomas of uncommon histology. 
  • Clinical spectrum and prognosis of follicular lymphoma with blastoid transformation: case series and a review of the literature. 
  • Clonal evolution in t(14;18)-positive follicular lymphoma, evidence for multiple common pathways, and frequent parallel clonal evolution. 
  • Clonally related composite follicular lymphoma and mantle cell lymphoma with clinicopathologic features and biological implications. 
  • Composite lymphoma of follicular B-cell and peripheral T-cell types with distinct zone distribution in a 75-year-old male patient: a case study. 
  • Dasatinib-associated follicular lymphoma in a patient with B-cell acute lymphoblastic leukaemia. 
  • First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors. 
  • Follicular T-cell lymphoma: a member of an emerging family of follicular helper T-cell derived T-cell lymphomas. 
  • Follicular lymphoma with hyaline-vascular Castleman disease-like follicles and CD20 positive follicular dendritic cells. 
  • Follicular lymphoma with hyaline-vascular Castleman-like features: analysis of 6 cases and review of the literature. 
  • Follicular lymphoma with prominent Dutcher body formation: a pathologic study of 3 cases in comparison with nodal or splenic lymphoplasmacytic lymphoma and marginal zone lymphoma. 
  • Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. 
  • High dose cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rhG-CSF) in the treatment of follicular, low grade non-Hodgkin's lymphoma: CALGB 9150. 
  • High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. 
  • Histiocytic sarcoma arising in indolent small B-cell lymphoma: report of two cases with molecular/genetic evidence suggestive of a 'transdifferentiation' during the clonal evolution. 
  • Histiocytic/dendritic cell transformation of B-cell neoplasms: pathologic evidence of lineage conversion in differentiated hematolymphoid malignancies. 
  • Immune signatures in follicular lymphoma. 
  • Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP. 
  • Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial. 
  • Low-grade follicular lymphoma of the small intestine: a challenge for management. 
  • Lymphoma-infiltrating immune cells. 
  • Multicenter, Open-Label, Phase II Study of Bendamustine and Rituximab Followed by 90-Yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe). 
  • NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019. 
  • Non-Hodgkin's lymphomas, version 2.2014. 
  • Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. 
  • Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103. 
  • Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance). 
  • Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia. 
  • Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. 
  • Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. 
  • Phase III randomized trial of patient-specific vaccination for previously untreated patients with follicular lymphoma in first complete remission: protocol summary and interim report. 
  • Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. 
  • Prominent Dutcher body formation in a case of follicular lymphoma with BCL6 gene rearrangement and intact BCL2 gene. 
  • Radiation Therapy for IDH-Mutant Grade 2 and Grade 3 Diffuse Glioma: An ASTRO Clinical Practice Guideline. 
  • Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). 
  • Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance). 
  • Recombinant interferon-alpha2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691. 
  • Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials. 
  • Revealing the evolution of the tumor immune microenvironment in follicular lymphoma patients progressing within 24 months using single-cell imaging mass cytometry. 
  • Rituximab for follicular lymphoma: watch and wait, watch and worry, or watch and live? 
  • Role of imaging in low-grade cutaneous B-cell lymphoma presenting in the skin. 
  • Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. 
  • Sequential development of histiocytic sarcoma and diffuse large b-cell lymphoma in a patient with a remote history of follicular lymphoma with genotypic evidence of a clonal relationship: a divergent (bilineal) neoplastic transformation of an indolent B-cell lymphoma in a single individual. 
  • Statin--a novel marker of nonproliferation. Expression in nonneoplastic lymphoid tissues and follicular lymphomas. 
  • The biology of human lymphoid malignancies revealed by gene expression profiling. 
  • The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials. 
  • Transformation of follicular lymphoma to precursor B-cell lymphoblastic lymphoma with c-myc gene rearrangement as a critical event. 
  • Treatment of non-Hodgkin's lymphoma with high-dose therapy and hematopoietic stem cell support. 
  • Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. 
  • Weight change trends and overall survival in United States veterans with follicular lymphoma treated with chemotherapy. 
• 

  Keywords of People

  • Rodgers, Thomas, Assistant Professor of Medicine, Duke Cancer Institute
  • Stefanovic, Alexandra, Associate Professor of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy
  • Stoecker, Maggie Marie, Assistant Professor of Pathology, Pathology